1. Home
  2. CYTK vs AX Comparison

CYTK vs AX Comparison

Compare CYTK & AX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • AX
  • Stock Information
  • Founded
  • CYTK 1997
  • AX 1999
  • Country
  • CYTK United States
  • AX United States
  • Employees
  • CYTK N/A
  • AX N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • AX Savings Institutions
  • Sector
  • CYTK Health Care
  • AX Finance
  • Exchange
  • CYTK Nasdaq
  • AX Nasdaq
  • Market Cap
  • CYTK 4.6B
  • AX 4.9B
  • IPO Year
  • CYTK 2004
  • AX 2005
  • Fundamental
  • Price
  • CYTK $35.39
  • AX $91.18
  • Analyst Decision
  • CYTK Buy
  • AX Strong Buy
  • Analyst Count
  • CYTK 13
  • AX 7
  • Target Price
  • CYTK $71.58
  • AX $90.43
  • AVG Volume (30 Days)
  • CYTK 1.7M
  • AX 327.3K
  • Earning Date
  • CYTK 08-07-2025
  • AX 10-29-2025
  • Dividend Yield
  • CYTK N/A
  • AX N/A
  • EPS Growth
  • CYTK N/A
  • AX N/A
  • EPS
  • CYTK N/A
  • AX 7.43
  • Revenue
  • CYTK $85,738,000.00
  • AX $1,203,093,000.00
  • Revenue This Year
  • CYTK $330.96
  • AX $12.79
  • Revenue Next Year
  • CYTK $73.41
  • AX $7.59
  • P/E Ratio
  • CYTK N/A
  • AX $12.28
  • Revenue Growth
  • CYTK 2635.74
  • AX 13.59
  • 52 Week Low
  • CYTK $29.31
  • AX $54.46
  • 52 Week High
  • CYTK $59.39
  • AX $92.99
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 49.60
  • AX 63.87
  • Support Level
  • CYTK $36.89
  • AX $89.71
  • Resistance Level
  • CYTK $39.92
  • AX $92.99
  • Average True Range (ATR)
  • CYTK 1.78
  • AX 1.76
  • MACD
  • CYTK -0.06
  • AX 0.21
  • Stochastic Oscillator
  • CYTK 54.96
  • AX 76.94

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About AX Axos Financial Inc.

Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment . The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.

Share on Social Networks: